Disease Course and Complement as Predictors of Response to Standard of Care Plus Placebo in Patients with SLE: A Post Hoc Analysis of Dapirolizumab Pegol and Epratuzumab Clinical Trial Data

被引:0
作者
Stach, Christian [1 ]
Gordon, Caroline [2 ]
Taieb, Vanessa [3 ]
Stojan, George [4 ]
Merrill, Joan [5 ]
机构
[1] UCB Pharma, Monheim, Germany
[2] Univ Birmingham, Inst Inflammat & Ageing, Birmingham, W Midlands, England
[3] UCB Pharma, Colombes, France
[4] UCB, Baltimore, MD USA
[5] Oklahoma Med Res Fdn, Oklahoma City, OK USA
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
1503
引用
收藏
页码:2965 / 2967
页数:3
相关论文
共 5 条
[1]  
[Anonymous], 2023, LANCET
[2]   Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials [J].
Clowse, Megan E. B. ;
Wallace, Daniel J. ;
Furie, Richard A. ;
Petri, Michelle A. ;
Pike, Marilyn C. ;
Leszczynski, Piotr ;
Neuwelt, C. Michael ;
Hobbs, Kathryn ;
Keiserman, Mauro ;
Duca, Liliana ;
Kalunian, Kenneth C. ;
Galateanu, Catrinel ;
Bongardt, Sabine ;
Stach, Christian ;
Beaudot, Carolyn ;
Kilgallen, Brian ;
Gordon, Caroline .
ARTHRITIS & RHEUMATOLOGY, 2017, 69 (02) :362-375
[3]   Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus [J].
Furie, Richard A. ;
Bruce, Ian N. ;
Doerner, Thomas ;
Leon, Manuel Gustavo ;
Leszczynski, Piotr ;
Urowitz, Murray ;
Haier, Birgit ;
Jimenez, Teri ;
Brittain, Claire ;
Liu, Jiajun ;
Barbey, Catherine ;
Stach, Christian .
RHEUMATOLOGY, 2021, 60 (11) :5397-5407
[4]   Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response [J].
van Vollenhoven, Ronald F. ;
Petri, Michelle A. ;
Cervera, Ricard ;
Roth, David A. ;
Ji, Beulah N. ;
Kleoudis, Christi S. ;
Zhong, Z. John ;
Freimuth, William .
ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (08) :1343-1349
[5]  
Wallace D, 2011, ARTHRITIS RHEUM-US, V63, pS885